治療的な新血管化のためのキニンB(1) 受容体を標的とする

Costanza Emanueli¹, Maria Bonaria Salis, Tiziana Stacca

¹Cardiovascular Medicine and Gene Therapy Section, National Laboratory of the National Institute of Biostructures and Biosystems, Osilo, Italy.

Circulation

|January 24, 2002

まとめ

キニンB1受容体は,肢体イシュケミアの治癒に不可欠です. この受容体を活性化すると,血管の成長と四肢の生存が促進され,血管疾患の治療標的として示唆されます.

科学分野:

心血管科学心血管科学
血管生物学血管生物学
再生医学は,再生医療である.

背景:

キニンは心血管機能を調節する.
強化されたキニン生成は,イシュケミアの後の組織治癒を助けます.

研究の目的:

肢体イシュケミアの後の修復性血管新生におけるキニンB(1) 受容体の役割を調査する.
エンドセリア細胞の増殖とアポトーシスに対する受容体効果を調べる.

主な方法:

薬理学的および遺伝的アプローチをマウインの肢体イシュケミアモデルで利用しました.
ヒト内皮細胞に関するインビトロ研究を実施した.
評価B(1) 受容体シグナル伝達,血管新生,細胞活力.

主要な成果:

B(1) 受容体シグナリングの廃止は,血管新生と血流の回復をひどく阻害しました.
B(1) ノックアウトマウスは,四肢の死滅と自動切断の高い割合を示した.
(1) レセプターアゴニストによる治療は,付随的成長を促進し, perfusion の回復を加速し,肢の回復を改善しました.
In vitroでは,B(1) の活性化により,内皮細胞の増殖と生存が促進され,対抗性によりアポトーシスが誘発された.

結論:

B1受容体は,不血性損傷に対する宿主防御反応に不可欠である.
B1受容体のシグナル伝達を強化することは,血栓不全性血管疾患の潜在的な治療戦略です.

さらに関連する動画

07:45

Harvest of Endothelial Cells from the Balloon Tips of Swan-Ganz Catheters after Right Heart Catheterization

Published on: January 23, 2019

08:22

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production

Published on: May 31, 2020

関連する概念動画

00:49

The Blood-brain Barrier

Overview

01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Antihypertensive Drugs: Action of β1 Blockers

01:17

Antihypertensive Drugs: Action of β₁ Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...

01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

関連する実験動画